


CORRECTION OPEN



Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Shukui Qin, Jin Li , Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, Kehe Chen, Peiguo Cao, Jianjun Xiao, Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Lin Han, Qingyu Wang, Jun Zhu and the Serplulimab-MSI-H Investigators*

© The Author(s), under exclusive licence to Springer Nature Limited 2022

British Journal of Cancer (2022) 127:2249; <https://doi.org/10.1038/s41416-022-02043-7>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-022-02001-3>, published online 19 October 2022

The original version of this article contained a mistake in the PDF as the corresponding author Jin Li is missing from the Consortia information. We apologize for the error. The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

*A list of authors and their affiliations appears online.

Published online: 2 November 2022